ArticleFrontiers in cardiovascular medicine2026
Effectiveness and safety of Guipi Mixture for the treatment of premature ventricular contractions (heart-spleen deficiency syndrome): study protocol for a randomized, double-blind, placebo-controlled, multicentre trial.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Premature ventricular contractions (PVCs) are a common arrhythmia. Long-term frequent PVCs may contribute to tachycardia-induced cardiomyopathy, exacerbate angina, or trigger more severe ventricular arrhythmias, increasing cardiovascular risk. Current Western guidelines recommend pharmacotherapy or catheter ablation, with conservative drug therapy (e.g., lidocaine, propafenone, metoprolol, amiodarone, verapamil) remaining the mainstay. Metoprolol tartrate, a first-line drug, is effective for PVCs but has single targets, limited efficacy, and potential long-term cardiovascular adverse effects. Traditional Chinese Medicine (TCM) offers high efficacy and low toxicity. Guipi Mixture, a Chinese patent medicine for heart-spleen deficiency syndrome, combined with Western medicine may overcome these limitations. This study evaluates the efficacy and safety of Guipi Mixture plus metoprolol for PVCs (heart-spleen deficiency syndrome). Methods: This is a randomized, double-blind, placebo-controlled, multicenter trial. Across 18 centers, 200 eligible subjects will be randomized (1:1) to intervention (Guipi Mixture + metoprolol) or control (Guipi Mixture placebo + metoprolol). The 12-week trial includes a 2-week screening, 2-week run-in, and 8-week treatment period. The primary outcome is the absolute change in 24 h PVC count from baseline to week 8 measured by ambulatory ECG (AECG). Secondary outcomes include responder rate (based on PVC reduction), SF-36 quality of life, PSQI sleep quality, TCM syndrome score, and ECG indicators. Adverse events will be recorded throughout the trial. Discussion: This study will provide evidence on the efficacy and safety of Guipi Mixture for PVCs (heart-spleen deficiency syndrome) and explore its impact on patients' quality of life. Clinical Trial Registration: http://itmctr.ccebtcm.org.cn/, identifier ITMCTR2025001333.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.